Table 1.
Association of miR-506-CDK6 expression with clinicopathologic variables
| Variable | miR-506- and CDK6-elevated patients (%) | Others (%) | p value |
|---|---|---|---|
| Sex | |||
| Male | 19 (42.2) | 26 (57.8) | 0.063 |
| Female | 7 (21.9) | 25 (78.1) | |
| Age (years) | |||
| ≤60 | 10 (25.0) | 30 (75.0) | 0.091 |
| >60 | 16 (43.2) | 21 (57.8) | |
| Smoking history | |||
| No | 11 (20.4) | 43 (79.6) | 0.00014 |
| Yes | 15 (65.2) | 8 (34.8) | |
| Recurrence | |||
| No | 17 (40.5) | 25 (59.5) | 0.173 |
| Yes | 9 (25.7) | 26 (74.3) | |
| Death | |||
| No | 6 (36.4) | 12 (63.6) | 0.816 |
| Yes | 20 (33.3) | 35 (66.7) | |
The group of miR-506, CDK6 elevated based on high expression of both miR-506 and CDK6 in lung cancer patients. p value calculated from Χ2 (Pearson chi square) test.